Results 31 to 40 of about 77,485 (311)
Неврология, нейропсихиатрия, психосоматика, 2022 Parkinson’s disease (PD) is a multifactorial neurodegenerative disease. Consequently, there has been growing interest in identifying early preclinical disease symptoms and searching for their laboratory markers in recent decades.Objective: to studythe ...
D. A. Novotnyy +8 more
doaj +1 more source
Health and Society, 2022 Botulinum neurotoxins (BoNT) are toxins produced by bacteria of the genus Clostridium botulinum and are considered as the most potent toxins nowadays. Firstly, known as a food poison, later explored as a biological weapon and currently considered a great therapeutic resource. Seven different BoNT serotypes (A-G) have already been identified. Among them,
Bruna Luiza Ribeiro de Almeida +2 more
openaire +2 more sources
The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells [PDF]
, 1989 The heavy and light chains of botulinum A toxin were separated by anion exchange chromatography. Their intracellular actions were studied using bovine adrenal chromaffin cells permeabilized with streptolysin O.
M. Gratzl +9 more
core +1 more source
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +13 more
core +1 more source
Recombinant botulinum neurotoxin serotype A1 in vivo characterization
Pharmacology Research & Perspectives, 2021 Clinically used botulinum neurotoxins (BoNTs) are natural products of Clostridium botulinum. A novel, recombinant BoNT type A1 (rBoNT/A1; IPN10260) has been synthesized using the native amino acid sequence expressed in Escherichia coli and has previously
Cindy Périer +13 more
doaj +1 more source
Botulinum toxin a in the treatment of blepharospasm - A 10-year experience [PDF]
, 2005 To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clinicas ...
Goncalves, LR +7 more
core +1 more source
Centaur antibodies: Engineered chimeric equine-human recombinant antibodies
Frontiers in Immunology, 2022 Hyper-immune antisera from large mammals, in particular horses, are routinely used for life-saving anti-intoxication intervention. While highly efficient, the use of these immunotherapeutics is complicated by possible recipient reactogenicity and limited
Ronit Rosenfeld +16 more
doaj +1 more source
On Botulinum Neurotoxin Variability [PDF]
mBio, 2015 ABSTRACT The rapidly growing number of botulinum neurotoxin sequences poses the problem of the possible evolutionary significance of the variability of these superpotent neurotoxins for toxin-producing Clostridium species. To progress in the understanding of this remarkable phenomenon, we suggest that researchers should (i) abandon an anthropocentric ...
MONTECUCCO, CESARE +1 more
openaire +4 more sources
Emerging Infectious Diseases, 2002 The potential threat of biological warfare with a specific agent is proportional to the susceptibility of the population to that agent. Preventing disease after exposure to a biological agent is partially a function of the immunity of the exposed ...
Arturo Casadevall
doaj +1 more source
Toxins, 2023 Botulinum neurotoxins (BoNTs) are important therapeutic agents. The in vivo median lethal dose (LD50) assay has been commonly used to measure the potency of BoNT commercial preparations.
Elena Fonfria +6 more
doaj +1 more source